Class / Patent application number | Description | Number of patent applications / Date published |
514100800 | Cystic fibrosis affecting | 22 |
20100323949 | ERYTHROPOIETIN MIMETIC PEPTIDE DERIVATIVE AND ITS PHARMACEUTICAL SALTS, THE PREPARATION AND USES THEREOF - What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R | 12-23-2010 |
20110039759 | Use of Secretin-Receptor Ligands in Treatment of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) - The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to the normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue. The invention provide method of treating cystic fibrosis or COPD in a patient by administering to said patient an effective amount of an agent which triggers anion efflux in respiratory tissue via the activation of the secretin receptor. | 02-17-2011 |
20110092413 | Albumin-Fused Kunitz Domain Peptides - The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer. | 04-21-2011 |
20110177999 | Therapeutic Combinations Useful in Treating CFTR Related Diseases - The present invention relates to therapeutic combinations and kits useful in treating CFTR-related diseases, such as cystic fibrosis. | 07-21-2011 |
20110201544 | Compositions and Methods for Inhibiting the Interaction between CFTR and CAL - The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface. | 08-18-2011 |
20110269667 | METHODS OF GENERATING AND USING PROCOLLAGEN - A method of promoting wound healing, treating fibrosis and/or promoting angiogenesis is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a procollagen, thereby promoting wound healing, treating fibrosis and/or promoting angiogenesis in the subject. | 11-03-2011 |
20110288005 | ALPHA 1-ANTITRYPSIN COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising alpha 1-antitrypsin linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of alpha 1-antitrypsin-related diseases, disorders, and conditions. | 11-24-2011 |
20110294720 | APRATOXIN THERAPEUTIC AGENTS: MECHANISM AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders. | 12-01-2011 |
20110319318 | COVALENT MILK PROTEIN/ISOTHIOCYANATE COMPLEXES - The present invention relates to the field of complexes. Embodiments of the present invention relate to food-grade covalent complexes containing at least one milk protein and at least one ITC-compound and to the uses of such complexes, e.g., to reduce the perceived pungency of ITC-compounds, to produce antimicrobial effects and/or to form and stabilize emulsions and/or foams. | 12-29-2011 |
20120071396 | Compositions and Methods for Inhibiting the Interaction Between CFTR and CAL - The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface. | 03-22-2012 |
20120122764 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP - The present invention provides a compound of formula I; | 05-17-2012 |
20120129760 | Modified peptides with antiviral properties and methods for obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective perorally in the treatment of many viral infections, such as influenza, herpes, and cytomegalovirus. | 05-24-2012 |
20120283169 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions | 11-08-2012 |
20140005098 | IGFBP-3 DERIVATIVES AND USES THEREOF | 01-02-2014 |
20140100155 | COMBINATION THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS - A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis. | 04-10-2014 |
20140235528 | INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY - Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase. | 08-21-2014 |
20140378372 | PEPTIDES AND METHODS OF USING SAME - We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases. | 12-25-2014 |
20150038403 | Compounds That Bind to the Erythropoietin Receptor - The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin. | 02-05-2015 |
20150038404 | MACROCYCLIC COMPOUNDS - This invention relates to novel macrocyclic compounds (e.g., those delineated in the formulae herein), pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the protease elastase. | 02-05-2015 |
20150290297 | IGFBP-3 DERIVATIVES AND USES THEREOF - The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders. | 10-15-2015 |
20150328203 | COMBINED THERAPY FOR CYSTIC FIBROSIS - There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ΔF508-CFTR mutation, and pharmaceutical compositions thereof. | 11-19-2015 |
20160120940 | METHODS AND USES OF SLIT FOR TREATING FIBROSIS - The present disclosure provides methods and uses of Slit protein and nucleic acid for inhibiting fibrosis and fibrotic-related disorders, for example, of the kidney, lung, heart, liver, or a wound. The Slit protein can be, for example, Slit2 or Slit2-N, or a Slit variant that can bind the Robo receptor and induce signalling. Also provided are pharmaceutical compositions comprising the Slit protein or nucleic acid and an additional anti-fibrotic agent. | 05-05-2016 |
20100249027 | CRF CONJUGATES WITH EXTENDED HALF-LIVES - The present invention relates to conjugates of CRF that have been modified to include a moiety that protects CRF from degradation and prolongs the half-life of CRF. The CRF conjugates of the invention have an increased half-life which results in a dose-sparing effect and less frequent administration | 09-30-2010 |
20110059891 | ALPHA-MSH THERAPIES FOR TREATMENT OF AUTOIMMUNE DISEASE - Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described. | 03-10-2011 |
20110160135 | SUPPRESSION OF NEUROENDOCRINE DISEASES - The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods. | 06-30-2011 |
20120077744 | STEROID-SPARING METHODS OF TREATING BRAIN EDEMA - The present invention relates to therapeutic regimens or protocols designed for the treatment, management or prevention of edema. In particular, the invention pertains to methods of treating or managing edema associated with brain tumors involving the administration of a therapeutically effective amount of corticorelin acetate that achieves a steroid-sparing effect. | 03-29-2012 |
20120122780 | Compounds, Compositions and Methods for Modulating Uric Acid Levels - Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 05-17-2012 |
20120135929 | Methods Of Modulating Uric Acid Levels - Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, a compound disclosed herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 05-31-2012 |
20140371147 | COMBINATION OF A PROSTAGLANDIN RECEPTOR AGONIST AND AN MC1R RECEPTOR AGONIST FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS - A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo. | 12-18-2014 |